VCA launches 35 cancer centers across North AmericaAugust 26, 2019Pets diagnosed with cancer will now have greater access to advanced, collaborative pet cancer care. VCA Animal Hospitals says it is launching 35 VCA Pet CancerCare Centers across North America, which will be staffed by multidisciplinary oncology teams that will design individualized treatment plans using the latest in medical health-care technology. Canadian centers are also slated for Laval and Brossard near Montreal, Quebec; Ottawa, Newmarket, Oakville, and Scarborough in Ontario; Victoria in British Columbia; and Calgary, Alberta. "At VCA Pet CancerCare Centers, we are leading cancer care into a hopeful new era with longer lifespans and improved quality of life," says Zack Wright, DVM, DACVIM/Oncology, director of oncology at VCA Animal Diagnostic Clinic in Dallas, Texas. "Our dedicated oncologists across the network are committed to working with primary care veterinarians to make advanced cancer care accessible to pet owners, with the goal always being extended, high quality of life for our patients." By introducing these cancer centers, VCA hopes to provide greater accessibility of world-class treatment to help improve the quality of life for pets, as well as to cultivate open lines of communication and collaboration between oncologists, primary care veterinarians, and pet owners. According to a VCA survey, 58 …
SPONSORED CONTENTLife Gets Busy, Stay ON POINT With Cytopoint®Simplify your approach to allergic pruritus with Cytopoint. Help maintain control of allergic itch when schedules get hectic for both veterinarians and pet owners alike. + Learn more
Zomedica, Celsee Inc. partner to deliver cancer liquid biopsy platformDecember 21, 2017Zomedica Pharmaceuticals Corp. has entered into a license and supply agreement with Celsee Inc., an innovator of progressive rare cell capture, characterization, and retrieval products in the emerging field of liquid biopsy. Under the terms of the agreement, Zomedica will have animal health exclusive global rights to develop and market Celsee's liquid biopsy platform for use by veterinarians as a cancer diagnostic. A liquid biopsy is a blood test with the potential to detect the presence of circulating tumor cells in the blood. Circulating tumor cells (CTC) are shed from a primary tumor into neighboring blood vessels and are transported throughout the body's circulatory system. The detection of CTCs in the blood could indicate a cancer diagnosis without the need for an invasive tissue biopsy, according to Zomedica. "Liquid biopsy is cutting-edge technology in human medicine right now and we're excited about the opportunity to develop and market this platform for use in veterinary medicine," stated Gerald Solensky, Jr., CEO at Zomedica. "We selected the Celsee platform because of the ease of use, workflow simplicity, and flexibility to use our novel canine biomarkers. If we successfully develop Celsee's technology, we believe we will be able to …
